{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.49","value":"-2.08"}]}],"title":"Global Health Status/QoL Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.43","value":"-6.67"}]}],"title":"Physical Functioning Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.61","value":"0.00"}]}],"title":"Role Functioning Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.98","value":"-6.25"}]}],"title":"Emotional Functioning Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.33","value":"4.17"}]}],"title":"Cognitive Functioning Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.61","value":"16.67"}]}],"title":"Social Functioning Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.42","value":"5.56"}]}],"title":"Fatigue Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.33","value":"-4.17"}]}],"title":"Pain Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.33","value":"4.17"}]}],"title":"Nausea and Vomiting Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.67","value":"-8.33"}]}],"title":"Dyspnea Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.22","value":"0.00"}]}],"title":"Insomnia Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.67","value":"8.33"}]}],"title":"Appetite Loss Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.67","value":"8.33"}]}],"title":"Constipation Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.67","value":"8.33"}]}],"title":"Diarrhea Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.67","value":"8.33"}]}],"title":"Financial Difficulties Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures such as functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Subscale scores are transformed to 0 to 100 scale, with higher scores on functional scales indicating better function and higher score on symptom scales indicating worse symptoms. Baseline is defined as the last non-missing measurement prior to JCARH125 infusion.","dispersionType":"Standard Deviation","groups":[{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG000","title":"Phase 2 600 x 10^6 Cells"}],"paramType":"MEAN","populationDescription":"All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol","reportingStatus":"POSTED","timeFrame":"Baseline and visit 24 month","title":"Change From Baseline in the Total Score of European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) in Phase 2","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}